Ocuphire Pharma Announces Completion of the First of Two Phase 2b Clinical Trials for Nyxol® Eye Drops Sep 4, 2019
Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development Aug 7, 2019
Ocuphire Pharma Raises Over $5 Million to Complete Multiple Late Phase 2 Clinical Trials Jul 22, 2019
Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China Apr 16, 2019
Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting Mar 27, 2019
